By Katherine Hamilton
Becton Dickinson and Co. said it plans to break off its bioscience and diagnostic solutions business to focus on medical technology.
Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and allow the company to invest more in innovation and margin growth.
The separation is scheduled to be completed in 2026, the company said.
After the separation, BD expects to have $17.8 billion in fiscal 2024 revenue. The biosciences and diagnostics business is expected to make $3.4 billion in revenue for that year.
BD expects to invest in research and development and capital allocation including mergers and acquisitions. Investments will focus on its businesses in medical manufacturing, medication management, biopharmaceuticals and chronic condition treatments.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
February 05, 2025 16:54 ET (21:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.